Amphotericin B Formulated in a Lipid Emulsion

Pascual B Ayestaran A Montoro JB Oliveras J Estibalez A Julia A . Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann Pharmacother 1995; 29: 1197–201.

Cleary JD Weisdorf D Fletcher CV . Effect of infusion rate on amphotericin B-associated febrile reactions. Drug Intell Clin Pharm 1988; 22: 769–72.

Kirsh R Goldstein R Tarloff J Parris D Hook J Hanna N . An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 1988; 158: 1065–70.

Joly V Farinotti R Saint-Julien L Cheron M Carbon C Yeni P . In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Antimicrob Agents Chemother 1994; 38: 177–83.

Fielding RM . Liposomal drug delivery: advantages and limitation from a clinical pharmacokinetic and therapeutic perspective. Clin Pharmacokinet 1991; 21: 155–64.

Joly V Bolard J Saint-Julien L Carbon C Yeni P . Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations. Antimicrob Agents Chemother 1992; 36: 262–6.

Wasan KM Brazeau GA Keyhani A Hayman AC Lopez-Berestein G . Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother 1993; 37: 246–50.

Janoff AS . Liposomes and lipid structures as carriers of amphotericin B. Eur J Clin Micro Infect Dis 1990; 9: 146–51.

Davis SS Washington C West P Illul L Liversidge G Sternson . Lipid emulsions as drug delivery systems. Ann NY Acad Sci 1987; 507: 75–89.

Washington C Lance M Davis SS . Toxicity of amphotericin B emulsion formulations. J Antimicrob Chemother 1993; 31: 806–8.

FDA safety alert: hazards of precipitation associated with parenteral nutrition. Thomas J McGinnis, Office of Health Affairs, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857.

Wells P . A guide to total nutrient admixtures: what you should know about this new approach to TPN. Chicago: Precept Press, 1992.

Rubin M Bilik R Aserin A Ziv Y Sinai Y Dintsman M . Catheter obstruction; analysis of filter content of total nutrient admixture. JPEN J Patenter Enteral Nutr 1989; 13: 641–3.

Mershon J Nogami W Williams JM Yoder C Eilzen HE Lemons JA . Bacterial-fungal growth in a combined parenteral nutrition solution. JPEN J Parenter Enteral Nutr 1986; 10: 498–502.

Trissel LA . Amphotericin B does not mix with fat emulsion. Am J Health-Syst Pharm 1995; 52: 1463–4.

Souzaa LC Maranhao RC Schreier S Campa A . In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with triglyceride-rich emulsion. J Antimicrob Chemother 1993; 32: 123–32.

Foster D Washington C Davis SS . Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. J Pharm Pharmacol 1988; 40: 325–8.

Lamb KA Washington C Davis SS Denyer SP . Toxicity of amphotericin B emulsion to cultured canine kidney cell monolayers. J Pharm Pharmacol 1991; 43: 522–4.

Chavanet P Joly V Rigaud D Bolard J Carbon C Yeni P . Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob Agents Chemother 1994; 38: 963–8.

Caillot D Chavanet P Casasnovas O Solary E Zanetta G Buisson M . Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Microbiol Infect Dis 1992; 11: 722–5.

Moreau P Milpied N Fayette N Ramee JF Harousseau JL . Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrobial Chemother 1992; 30: 535–41.

Caillot D Reny G Solary E Casasnovas O Chavanet P Bonnotte B . A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother 1994; 33: 603–13.

Chavanet PY Garry I Charlier N Caillot D Kisterman JP D'Athis M . Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ 1992; 305: 921–5.

Caillot D Casasnovas O Solary E Chavanet P Bonnotte B Reny G . Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidemia in neutropenic patients. J Antimicrob Chemother 1993; 31: 161–9.

Smith TM Strozyk WR . Lack of nephrotoxicity with the administration of amphotericin B in a lipid emulsion. Ann Pharmacother 1994; 28: 1307–8.

Fisher MA Talbot GH Maislin G McKeon BP Tynan KP Strom BL . Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 1989; 87: 547–52.

Wasan KM Grossie VB Lopez-Berestein G . Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous Intralipid infusion. Antimicrob Agents Chemother 1994; 38: 2224–6.

Cleary JD Nolan RL Chapman SW . Inhibition of interleukin 1 release from endotoxin or amphotericin B stimulated monocytes. Antimicrob Agents Chemother 1992; 36: 977–81.

Hoeprich PD . Clinical use of amphotericin B and derivative: lore, mystique, and fact. Clin Infect Dis 1992; 14 (suppl): S114–9.

Cleary JD Chapman SW Clark AC Luchia H . Antimycotic pharmacotherapy. In: Koda-Kimble MA Young LY , eds. Applied therapeutics. 6th ed. Vancouver, WA: Applied Therapeutics, 1995: 69–12.